Table 2 Mean ± standard error values across 11 subjects of ADC (isotropic), ADC (S/I), T1, \({AUC}_{90s}\), \({v}_{p}\), \({k}^{trans}\), and \({v}_{e}\) in various tissues at baseline.

From: Dose–response assessment by quantitative MRI in a phase 1 clinical study of the anti-cancer vascular disrupting agent crolibulin

Tissue

ADC (× 10−3 mm2/s)

ADC (S/I) (× 10−3 mm2/s)

T1 (1.5T/3T) (s)

AUC90s (mM s)

vp

ktrans (min−1)

ve

Whole tumor

2.1 ± 0.3 (n = 15)

2.4 ± 0.2 (n = 15)

0.7 ± 0.1/0.8 ± 0.1 (n = 11)/(n = 5)

34.2 ± 7.8 (n = 13)

0.14 ± 0.04 (n = 13)

0.31 ± 0.12 (n = 13)

0.37 ± 0.10 (n = 13)

Tumor rim

1.7 ± 0.3 (n = 10)

2.1 ± 0.2 (n = 10)

0.8 ± 0.0/0.8 ± 0.1 (n = 10)/(n = 3)

39 ± 9.3 (n = 11)

0.16 ± 0.05 (n = 11)

0.35 ± 0.15 (n = 11)

0.37 ± 0.06 (n = 11)

Tumor core

1.8 ± 0.4 (n = 10)

2.1 ± 0.2 (n = 10)

0.7 ± 0.1/0.8 ± 0.1 (n = 10)/(n = 3)

36.4 ± 10.7 (n = 11)

0.15 ± 0.06 (n = 11)

0.32 ± 0.14 (n = 11)

0.17 ± 0.17 (n = 11)

Muscle

1.4 ± 0.2 (n = 11)

1.5 ± 0.1 (n = 11)

0.7 ± 0.1/0.9 ± 0.0 (n = 6)/(n = 4)

7 ± 1.7 (n = 8)

0.02 ± 0.00 (n = 8)

0.06 ± 0.02 (n = 8)

0.14 ± 0.04 (n = 8)

Spleen

1.3 ± 0.2 (n = 7)

1.5 ± 0.2 (n = 7)

0.8 ± 0.0/0.8 (n = 5)/(n = 1)

97 ± 22 (n = 5)

0.72 ± 0.16 (n = 5)

1.03 ± 1.01 (n = 5)

0.32 ± 0.29 (n = 5)

Liver

1.2 ± 0.2 (n = 8)

1.3 ± 0.2 (n = 8)

0.8 ± 0.1/0.9 ± 0.0 (n = 6)/(n = 2)

29 ± 6.6 (n = 6)

0.02 ± 0.04 (n = 6)

0.86 ± 0.42 (n = 6)

0.47 ± 0.13 (n = 6)

Renal cortex

2.9 ± 0.4 (n = 5)

2.9 ± 0.3 (n = 5)

0.9/– (n = 1)/-

95 (n = 1)

0.63 (n = 1)

0.91 (n = 1)

0.74 (n = 1)

Back to article page